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Abstract
Familial hypercholesterolemia is an inherited condition that causes patients
to have significantly increased levels of LDL cholesterol, which often leads
to coronary artery disease. Statin medications are typically prescribed to
treat this condition, however these medications have adverse side effects and
often subpar efficacy in this patient population. Evidence collected in this
literature review yielded evidence that the use of PCSK9 inhibitors in the
treatment of patients with familial hypercholesterolemia may be efficacious.
Many of these studies were able to show statistically significant improvement
of LDL-C and decrease in cardiovascular risk when compared to placebo. In
addition, this medication was found to be tolerated well without adverse side
effects, most notably in patients with a statin intolerance. Although more
research is needed, PCSK9 inhibitors seem to be efficacious compared to
standard of care in improving LDL-C and lowering the risk of cardiovascular
events in patients with familial hypercholesterolemia.

Introduction
•
•
•
•

OVERVIEW: Familial hypercholesterolemia
autosomal dominant inheritance - 10 million people living with FH
causes high plasma levels of LDL cholesterol - regardless of their
lifestyle & diet habits
20-fold increase in premature coronary artery disease
20% of myocardial infarctions under age 45 & 5% of myocardial
infarctions under age 60 due to FH

STANDARD OF CARE:
• first line treatment: lifestyle & diet modifications
• those with FH often still have high cholesterol
• first line medications: statins
• highest dose often doesn’t bring down LDL-C in pts with FH
• Side Effects: muscle aches/weakness, neuro-cognitive
impairments, liver damage, GI upset.

Methods

Results

Discussion

• 5/6 found % of LDL-C reduction of 50% or more

PCSK9i are effective in lowering LDL-C & cardiovascular risk in
patients with familial hypercholesterolemia

• 2/4 achieved patients LDL-C goals

Strengths:

• 2/2 of the studies looking at the reduction of cardiovascular
events found a statistically significant reduction.

• recruitment methods: use of healthcare professionals to recruit
patients with existing FH diagnosis or statin intolerant patients

• 3/6 found at least 5% of participants had reported significant
side effects

• observer bias unlikely in most of the studies

• injection site reactions, GI side effects, or transaminase
elevation.

Weaknesses:
• short study duration with no long term follow-up

• 2/2 of the studies that evaluating the non-adherence due to
cost, the cost was found to be a significant barrier for patients.

• small sample size - highest at 511

Table 1. Comparison of Results

• no research on use in pediatric population

Study

LDL-C
reduction
(%)
S

Reported
Side Effects
NS

Reduction of
Cardiovascular
Events
N/A

NS

S

Zafrir et al

S

Hovingh et al

Dufour et al

LDL-C goals Non-adherence
achieved due to Cost
S

N/A

N/A

N/A

N/A

S

S

S

S

S

NS

N/A

N/A

N/A

Nissen et al

S

S

N/A

NS

N/A

Olry de
Labry et al

S

NS

S

NS

S

Raal et al

Key: S = significant; NS = not significant
LDL-C reduction

Side Effects

S = LDL-C reduction S = 5% of participants
of 50% or more
reporting significant side
effect
NS = less than 50%
reduction in LDLSafter PCSK9I
treatment

NS = less than 5%
reporting significant side
effects

Cardiovascular Event
Reduction

LDL-C goals achieved

Non-adherence due to Cost

S = 70% achieving LDL-C
S = cost was a barrier for patients
S = reduction in cardiovascular goals with PCSK9i medication
events
NS = no reported cost-effectiveness
NS = LDL-C goals not
issues
NS = no reduction in
achieved with use of
cardiovascular events with
medication
PCSK9i treatment

Table 2. Validity assessment information used for the evidence
Study

Blinding

Statistical
power

Dufour et al
Raal et al
Zafrir et al
Hovingh et al
Nissen et al
Olry de
Labry et al

I
A
N/A
I
A
N/A

M
M
M
A
A
A

Adequate
treatment
timeline
A
I
A
A
M
A

• low diversity in terms of race & country of administration

Recruitment
Strategies

Bias

A
A
A
A
A
M

M
M
I
M
A
A

Future Focus
patient
adherence

long term effects

cost
effectiveness

synergistic
effects with other
medications

Conclusion
PCSK9i should be considered as a possible therapeutic treatment in the
management of patients with familial hypercholesterolemia, especially if the
patient is statin intolerant. These medications are effective in lowering the
patients LDL-C and cardiovascular risk as evidenced by the six studies
selected for review. Although study designs and observer bias prevents these
results from achieving clinical significance, there is promising evidence.
Further research into this topic is warranted to address the shortcomings of
current studies and confirm current research findings. In addition, studies
including cost analysis and real world use as a therapy need to be assessed
since cost is a big factor in patient adherence.
Further research will hopefully demonstrate the long term effectiveness vs
cost of the medication and its use in clinical practice as a standard treatment of
familial hypercholesterolemia.
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